Dr. Breitmeyer, a Board certified Medical Oncologist, has over 25 years of experience in the pharmaceutical industry, most recently as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian Nordic A/S where he was responsible for the successful licensing of an oncology asset to BMS for $975M.

He held executive leadership positions at Zogenix Inc. where he remains a Director, Cadence Pharmaceuticals, Inc. (acquired by Mallinkrodt), Applied Molecular Evolution (acquired by Eli Lilly and Company), Serono Laboratories (acquired by Merck KGaA), and was the founding President and CEO of the Harvard Clinical Research Institute. He has led efforts resulting in eight FDA and/or international product approvals including Zohydro®, Ofirmev®, Rebif®, Saizen®, Geref®, Serostim®, Fertinex®, and Gonal-F®.